Jon Paul Gockerman, MD

Professor Emeritus of Medicine
Campus mail 25154 Morris Bldg, Durham, NC 27710
Phone (919) 684-8964
Email address gocke002@mc.duke.edu

My research effort is involved in clinical research studies through the CALGB as well as several sub interests. My interest is the use of 131I MIBG in the treatment of carcinoids. We have completed a dose seeking study to determine the maximum tolerated dose. This has been completed and this paper is in preparation for publication. We plan to do an additional study of randomization in patients with this agent to see if we can determine an objective response rate in a controlled group of patients.

The secondary issue is that of high dose chemotherapy in lymphoma. We have completed a study involving use of high dose chemotherapy in a transplant setting in patients with refractory lymphoma. This study has treated over 100 patients and is in the process of being written up.

Education and Training

  • M.D., University of Chicago, 1967

Publications

Morris, Tod A., Carlos M. DeCastro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Zhiguo Li, Joseph O. Moore, David A. Rizzieri, and Arati V. Rao. “Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia..” Leuk Res 37, no. 1 (January 2013): 28–31. https://doi.org/10.1016/j.leukres.2012.09.016.

PMID
23046833
Full Text

DiLillo, D. J., J. B. Weinberg, A. Yoshizaki, M. Horikawa, J. M. Bryant, Y. Iwata, T. Matsushita, et al. “Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function..” Leukemia 27, no. 1 (January 2013): 170–82. https://doi.org/10.1038/leu.2012.165.

PMID
22713648
Full Text

Rao, A. V., D. A. Rizzieri, C. M. DeCastro, L. F. Diehl, A. S. Lagoo, J. O. Moore, and J. P. Gockerman. “Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML.” Journal of Geriatric Oncology 3, no. 3 (July 1, 2012): 220–27. https://doi.org/10.1016/j.jgo.2012.02.002.

Full Text

Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors..” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.

PMID
22638798
Full Text

Lanasa, Mark C., Patricia H. Davis, Michael Datto, Zhiguo Li, Jon P. Gockerman, Joseph O. Moore, Carlos M. DeCastro, et al. “Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia..” Leuk Lymphoma 53, no. 2 (February 2012): 218–24. https://doi.org/10.3109/10428194.2011.610012.

PMID
21827374
Full Text

Ettinger, David S., Mark Agulnik, Justin M. M. Cates, Mihaela Cristea, Crystal S. Denlinger, Keith D. Eaton, Panagiotis M. Fidias, et al. “NCCN Clinical Practice Guidelines Occult primary..” J Natl Compr Canc Netw 9, no. 12 (December 2011): 1358–95. https://doi.org/10.6004/jnccn.2011.0117.

PMID
22157556
Full Text

Christensen, Dale J., Youwei Chen, Jessica Oddo, Karen M. Matta, Jessica Neil, Evan D. Davis, Alicia D. Volkheimer, et al. “SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target..” Blood 118, no. 15 (October 13, 2011): 4150–58. https://doi.org/10.1182/blood-2011-04-351072.

PMID
21844565
Full Text

Lanasa, M. C., S. D. Allgood, S. L. Slager, S. S. Dave, C. Love, G. E. Marti, N. E. Kay, et al. “Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL..” Leukemia 25, no. 9 (September 2011): 1459–66. https://doi.org/10.1038/leu.2011.117.

PMID
21617698
Full Text

Schuster, Stephen J., Sattva S. Neelapu, Barry L. Gause, John E. Janik, Franco M. Muggia, Jon P. Gockerman, Jane N. Winter, et al. “Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma..” J Clin Oncol 29, no. 20 (July 10, 2011): 2787–94. https://doi.org/10.1200/JCO.2010.33.3005.

PMID
21632504
Full Text

Nalesnik, M. A., E. S. Woodle, J. M. Dimaio, B. Vasudev, L. W. Teperman, S. Covington, S. Taranto, et al. “Donor-transmitted malignancies in organ transplantation: assessment of clinical risk..” Am J Transplant 11, no. 6 (June 2011): 1140–47. https://doi.org/10.1111/j.1600-6143.2011.03565.x.

PMID
21645251
Full Text

Pages